GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Black Diamond Therapeutics Inc (NAS:BDTX) » Definitions » Tax Expense

Black Diamond Therapeutics (Black Diamond Therapeutics) Tax Expense : $0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Black Diamond Therapeutics Tax Expense?

Black Diamond Therapeutics's tax expense for the months ended in Mar. 2024 was $0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.


Black Diamond Therapeutics Tax Expense Historical Data

The historical data trend for Black Diamond Therapeutics's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Black Diamond Therapeutics Tax Expense Chart

Black Diamond Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Tax Expense
Get a 7-Day Free Trial - - - - -

Black Diamond Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Black Diamond Therapeutics Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Black Diamond Therapeutics  (NAS:BDTX) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Black Diamond Therapeutics Tax Expense Related Terms

Thank you for viewing the detailed overview of Black Diamond Therapeutics's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Black Diamond Therapeutics (Black Diamond Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
One Main Street, 14th Floor, Cambridge, MA, USA, 02142
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-189 and BDTX-1535.
Executives
Biotech Growth N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Ra Capital Nexus Fund, L.p. director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ali Behbahani director, 10 percent owner 5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Peter Kolchinsky director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Healthcare Fund Lp director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
David M. Epstein director, officer: See Remarks OSI PHARMACEUTICALS, INC., 41 PINELAWN ROAD, MELVILLE NY 11747
Sergey Yurasov officer: CHIEF MEDICAL OFFICER C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E., SUITE 310, SEATTLE WA 98102
Elizabeth Buck officer: CHIEF SCIENTIFIC OFFICER C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA 02142
Erika Jones officer: SEE REMARKS C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA 02142
Fang Ni officer: SEE REMARKS C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA 02142
Biotech Ag Bb 10 percent owner SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200
Wendy L Dixon director
Mark A. Velleca director 79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Brent Hatzis-schoch officer: See Remarks C/O RADIUS HEALTH, INC., 950 WINTER STREET, WALTHAM MA 02451

Black Diamond Therapeutics (Black Diamond Therapeutics) Headlines

From GuruFocus

Black Diamond Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

By Stock market mentor Stock market mentor 01-05-2023